| Date | Title | Description |
| 12.06.2024 | Xyzal® Helps Music Festival Goers Conquer Allergies and Seize the Day (or Night!) | Xyzal® is elevating the festival experience for fans nationwide at Tortuga Music Festival, Shaky Knees Music Festival and Sea.Hear.Now Festival this year.
BRIDGEWATER, N.J., June 12, 2024 /PRNewswire/ -- Music festivals are all about unforg... |
| 16.03.2023 | Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance | Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance
Paris, March 16, 2023. Sanofi announces that it will cut the list price of Lan... |
| 04.02.2022 | FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease | FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease Enjaymo is the only approved treatment to decrease the need for red blood cell transfusion due to hemolysis, the destruction of red bl... |
| 24.01.2020 | Sanofi Closes Purchase of Synthorx | Sanofi (NASDAQ: SNY; EURONEXT: SAN), a global biopharmaceutical company focused on human health, completed the acquisition of Synthorx, Inc., La Jolla, CA-based clinical-stage biotechnology company, for $68 per share in cash.
In conjunction... |
| 04.06.2018 | Sanofi is the latest drug maker to say average net prices fell last year | Amid heated controversy over drug prices, Sanofi (SNY) is the latest large pharmaceutical company to release top-line numbers indicating average prices for its medicines fell last year, after accounting for rebates and discounts.
Specifical... |
| 03.06.2014 | WWDC Keynote Shows Apple Means Business | Apple’s WWDC keynote had a message for cloud service providers. Apple knows it has the devices inside the enterprise, whether iPhone, iPad and even Macs, and it wants more than just the hardware business. It wants everything. And it’s comin... |
| 21.05.2014 | MassChallenge Names 128 Startups to 2014 Accelerator Class | "We are incredibly grateful to our judges and partners for helping us to identify the startups that will drive global impact, said MassChallenge Founder and President Akhil Nigam. We look forward to working with the MassChallenge commu... |
| 24.02.2014 | Medtech industry: In this ACO world, take pricing cues from biopharma, posthaste | “That’s critical for today. Short-term: I need that pricing capability now,” he said.
While medtech may be held back by long contracting cycles for pricing, in a healthcare landscape ever more ACO-driven, innovative pricing strategies will ... |
| 01.10.2013 | Organ-on-a-chip producer collaborates with Sanofi in medtech-pharma mashup | Hurel will conduct some of the studies in its laboratories in North Brunswick, New Jersey and will work with Sanofi R&D at sites in the U.S. and Europe. The results of the study will be published in at least one co-authored, peer-review... |
| 13.12.2012 | Expanding tools for clinical research, rare disease network gets Sanofi award | The competition began earlier this year at the Partners in Patient Health Forum in Washington, DC. The challenge required two or more groups to collaborate in order to qualify for the contest and designed to promote sharing of complementary... |
| 14.11.2012 | Flu tracker, Alzheimer’s disease test among Sanofi patient advocacy competition finalists | Crowdsourcing competitions have been a growing trend among healthcare and pharmaceutical companies as a way to generate effective approaches for improving patient outcomes and reducing unnecessary hospitalization costs. A division of Jansse... |
| 03.08.2012 | Sanofi-Aventis colorectal cancer drug secures FDA approval in important step for cancer unit | “Zaltrap isn’t likely to be a large medicine for Sanofi, but getting a cancer drug approved is important for them after a series of setbacks in oncology,” said Pierre Corby, an analyst at Aurel BGC in Paris.
Zaltrap was proven to extend lif... |
| 24.07.2012 | Patient advocacy problem solving gets put to the test in new Sanofi competition | The teams are encouraged to demonstrate creative problem-solving skills and define the target audience, proposed impact, time frame and the measures for the idea’s success, according to the competition’s website.
The competition is open unt... |
| 16.07.2012 | Big data group with patient-tracking plan gets Sanofi’s diabetes award | In a blog post last month on the website Sanofi set up for the competition, n4a said:
The American Diabetes Association’s estimate of 12 percent compliance translates to about 25 million people with diabetes today who are taking unnecessary... |
| 12.07.2012 | Biotech with Lysosomal storage disorder treatment raising $3.5 million, doubles staff | Hung Do, the chief science officer of Callidus Biopharma, based at the Pennsylvania Biotechnology Center in Doylestown, Pennsylvania, told MedCity News that he believes the enzyme replacement therapies currently on the market are inefficien... |
| 20.06.2012 | FDA panel gives thumbs down to Sanofi blood thinner for patients on chemo | MedPage Today noted that committee members repeatedly questioned whether the patient population and chemotherapy drug for the study were appropriate. It also called attention to the stilted exchange between the drugmaker and the regulators.... |
| 02.04.2012 | Former head of Sanofi vaccines division becomes infectious disease biotech CEO | Last year, it was granted a five-year research grant valued up to $196 million by the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, to fund the development of seasonal and ... |
| 26.03.2012 | Welcome to the Matrix: using virtual reality to develop global clinical trials | In response to the question of why he developed avatars and how they help with the learning process, Burns said that with such an enormous amount of data that’s being transmitted in meetings, content without context is meaningless.
“People ... |
| 20.01.2012 | Lysosomal storage disorder treatment moving into proof-of-concept phase | Do said although a handful of FDA-approved protein therapies, enzyme replacement therapies (ERTs) were developed to treat lysosomal storage diseases, the ERTs are not “optimal.” He explained that the current therapies each have deficiencies... |
| 10.01.2012 | U.S. healthcare spending slows down, HHS report says (Morning read) | Warp Drive Bio launches. A new life science venture called Warp Drive Bio takes off with a $125 million initial investment from Sanofi (NYSE:SNY). Warp Drive has developed a proprietary genomics platform to “unlock nature’s drugs and ultima... |
| 19.12.2011 | Scynexis aims to raise $15M; hepatitis C drug candidate in phase 2 trials | Scynexis collaborates with pharmaceutical companies on their drug discovery and development efforts and it already has a long list of drug partners that include Merck (NYSE:MRK), Sanofi (NYSE:SNY) and Roche (OTC:RHHBY). In the last five yea... |
| 17.10.2011 | Medical device firm Chesson Labs raises $1.5M | The liquid bandage Nuvaderm was cleared for use in superficial cuts and scrapes. Chesson also has a similar product for animals called Nuvavet. Research firm Global Markets Direct forecasts the global market for wound care management will t... |
| 13.01.2009 | BiPar snags $20M for inhibitor-based cancer therapies | Pharmaceutical firm BiPar Sciences just brought in $20 million in private equity and venture debt to advance its lead therapy, targeting breast cancer, to phase-three clinical trials. The investment will double the Brisbane, Calif.-based co... |
| - | U.S. healthcare spending slows down, HHS report says (Morning read) | Current medical news and unique business news for anyone who cares about the healthcare industry.
Healthcare spending slowdown. U.S. healthcare spending grew 3.9 percent in 2010, reaching $2.6 trillion, according to a new report from the U.... |
| - | FDA panel gives thumbs down to Sanofi blood thinner for patients on chemo | A U.S. Food and Drug committee moved against recommending for approval Sanofi-Aventis’ (NYSE:SNY) blood thinner for patients on chemotherapy in a resounding 14 to 1 vote against semuloparin.
Semuloparin was designed to treat patients with c... |
| - | Big data group with patient-tracking plan gets Sanofi’s diabetes award | A big data group with a plan to reduce the cost of diabetes care by identifying and tracking people in the early stages of diabetes who under use healthcare emerged as the winner of Sanofi’s (NYSE:SNY) crowdsourcing competition to uncover i... |
| - | Flu tracker, Alzheimer’s disease test among Sanofi patient advocacy competition finalists | A competition by Sanofi US (NYSE: SNY) intended to improve patient engagement and spur people to take a more active role in their healthcare has whittled the entries down to four finalists. The selected entries span common illnesses like fl... |
| - | Lysosomal storage disorder treatment moving into proof-of-concept phase | A company formed to develop protein therapeutics to treat lysosomal storage diseases — rare genetic disorders that affect the metabolism of certain natural biological substances in cells — is raising $5 million in a series A financing round... |
| - | Former head of Sanofi vaccines division becomes infectious disease biotech CEO | The former head of Sanofi’s (NYSE:SNY) vaccines division, one of the largest vaccine companies in the world, has joined a biotechnology company developing infectious disease vaccines as its CEO.
Wayne Pisano will lead Cranbury, New Jersey-b... |
| - | Medical device firm Chesson Labs raises $1.5M | Medical device company Chesson Labs has raised $1.45 million in a second round of financing targeting $2 million.
The Durham, North Carolina company disclosed the new financing in an amended securities filing. The current round of financing... |
| - | Welcome to the Matrix: using virtual reality to develop global clinical trials | In a bid to address the reality of global clinical trials among life science companies, one business has developed software to facilitate business collaboration meetings taking place between multiple parties in different locations and conti... |
| - | Medtech industry: In this ACO world, take pricing cues from biopharma, posthaste | By now, you’ve heard the medical device industry landscape is shifting. The term “innovation” needs new life breathed into it in the life sciences, major companies are turning over their business models to take a larger bite of the care con... |
| - | Biotech with Lysosomal storage disorder treatment raising $3.5 million, doubles staff | A biotechnology company co-founded by a pharmaceutical industry veteran is raising an additional $3 million as part of a Series A round to advance its lead therapeutic for Lysosomal storage disorders to the clinical trial stage. It has rais... |
| - | Organ-on-a-chip producer collaborates with Sanofi in medtech-pharma mashup | Pharmaceutical companies’ search for ways to trim costs on research and development is leading them to try out some alternative technologies to achieve that. Organ-on-a-chip, aka human-on-a-chip, fits that description.
Sanofi US is collabor... |
| - | Sanofi-Aventis colorectal cancer drug secures FDA approval in important step for cancer unit | A colorectal cancer drug developed by Sanofi-Aventis (NYSE:SNY) and Regeneron Pharmaceuticals (NASDAQ:REGN) has received approval from the U.S. Food and Drug Administration.
Zaltrap is designed to be used in combination with folinic acid, f... |
| - | Patient advocacy problem solving gets put to the test in new Sanofi competition | Patient advocacy groups are being encouraged to work together to improve patient outcomes as part of a new innovation challenge launched this week by Sanofi US.
For the Collaborate Activate Challenge, groups made up of patient advocates, ca... |
| - | Scynexis aims to raise $15M; hepatitis C drug candidate in phase 2 trials | Drug discovery and development firm Scynexis, which is moving forward on a new hepatitis C treatment, has raised $5 million in a fundraising effort targeted to reach up to $15 million.
A total of nine investors have invested in the round th... |
| - | Expanding tools for clinical research, rare disease network gets Sanofi award | A patient-centric tool to provide a virtual research network for rare diseases to improve clinical trial recruitment has taken the top prize in an innovation challenge from Sanofi US.
Registries for All Diseases will get $300,000 to create ... |
